Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Tessa Brabander(Erasmus MC), Dik J. Kwekkeboom(Erasmus MC), Wouter A. van der Zwan(Erasmus MC), Jaap J.M. Teunissen(Erasmus MC), Richard A. Feelders, Boen L.R. Kam(Erasmus MC), Gaston J H Franssen(Erasmus MC), Casper H.J. van Eijck(Erasmus MC), Eric P. Krenning(Erasmus MC), Wouter W. de Herder(Erasmus University Rotterdam)
Cited by 604
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914